deltatrials
Completed NA INTERVENTIONAL 2-arm NCT01483027

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Sponsor: Biocompatibles UK Ltd

Conditions Colorectal Cancer Metastatic
Interventions TheraSphere
Updated 19 times since 2017 Last updated: Mar 3, 2022 Started: Jan 31, 2012 Primary completion: Aug 31, 2020 Completion: Aug 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Colorectal Cancer Metastatic, this trial is completed. The trial is conducted by Biocompatibles UK Ltd and has accumulated 19 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Jun 2020 · 11 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Apr 2022 · 11 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed NA

  2. Sep 2025 — Present [monthly]

    Completed NA

  3. Sep 2024 — Sep 2025 [monthly]

    Completed NA

  4. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  5. Apr 2022 — Jul 2024 [monthly]

    Completed NA

▶ Show 14 earlier versions

  1. May 2021 — Apr 2022 [monthly]

    Completed NA

  2. Apr 2021 — May 2021 [monthly]

    Completed NA

  3. Feb 2021 — Apr 2021 [monthly]

    Completed NA

    Status: Active Not Recruiting → Completed · Phase: PHASE3 → NA

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2019 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE3

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  12. Sep 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  13. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biocompatibles UK Ltd
  • Boston Scientific Corporation
Data source: Boston Scientific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Aberdeen, United Kingdom , Alcorcón, Spain , Angers, France , Ann Arbor, United States , Aurora, United States , Barcelona, Spain , Bath, United Kingdom , Bebington, United Kingdom , Bialystok, Poland and 101 more locations